- Home
- MNPR vs CAAS Comparison
MNPR vs CAAS Comparison
Compare MNPR & CAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- CAAS
- Stock Information
- Founded
- MNPR 2014
- CAAS N/A
- Country
- MNPR United States
- CAAS China
- Employees
- MNPR N/A
- CAAS N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- CAAS Auto Parts:O.E.M.
- Sector
- MNPR Health Care
- CAAS Consumer Discretionary
- Exchange
- MNPR Nasdaq
- CAAS Nasdaq
- Market Cap
- MNPR 113.5M
- CAAS 111.1M
- IPO Year
- MNPR 2019
- CAAS N/A
- Fundamental
- Price
- MNPR $30.68
- CAAS $3.90
- Analyst Decision
- MNPR Strong Buy
- CAAS
- Analyst Count
- MNPR 3
- CAAS 0
- Target Price
- MNPR $27.33
- CAAS N/A
- AVG Volume (30 Days)
- MNPR 93.6K
- CAAS 35.5K
- Earning Date
- MNPR 11-08-2024
- CAAS 11-13-2024
- Dividend Yield
- MNPR N/A
- CAAS N/A
- EPS Growth
- MNPR N/A
- CAAS 2.02
- EPS
- MNPR N/A
- CAAS 1.05
- Revenue
- MNPR N/A
- CAAS $621,377,000.00
- Revenue This Year
- MNPR N/A
- CAAS $4.97
- Revenue Next Year
- MNPR N/A
- CAAS N/A
- P/E Ratio
- MNPR N/A
- CAAS $3.99
- Revenue Growth
- MNPR N/A
- CAAS 13.81
- 52 Week Low
- MNPR $1.55
- CAAS $3.05
- 52 Week High
- MNPR $38.50
- CAAS $4.97
- Technical
- Relative Strength Index (RSI)
- MNPR 76.63
- CAAS 31.61
- Support Level
- MNPR $20.16
- CAAS $4.32
- Resistance Level
- MNPR $25.97
- CAAS $4.52
- Average True Range (ATR)
- MNPR 2.75
- CAAS 0.19
- MACD
- MNPR 0.41
- CAAS -0.04
- Stochastic Oscillator
- MNPR 90.25
- CAAS 2.86
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About CAAS China Automotive Systems Inc.
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, more than 310 models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.